Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manim PFS is a pharmaceutical injection containing methylcobalamin (1500 mcg/ml), a bioactive form of Vitamin B12, developed by Maan Pharmaceuticals. It is supplied in a pre-filled syringe (PFS) for the treatment of peripheral neuropathy, vitamin B12 deficiency, and megaloblastic anemia. Methylcobalamin serves as an essential cofactor for the enzyme methionine synthase, which converts homocysteine to methionine. This process is critical for DNA synthesis and the maintenance of the myelin sheath surrounding neurons. By promoting protein synthesis and neural repair pathways, Manim PFS supports nerve regeneration and helps alleviate symptoms like numbness, tingling, and muscle weakness associated with nerve damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Manim PFS.